Latest HspE7 Stories

SAN DIEGO, July 28 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced that it has completed analysis of immunological data from all four cohorts of its Phase 1 clinical trial for HspE7, its lead product candidate. HspE7 is a therapeutic treatment for patients with cervical intraepithelial neoplasia, or CIN, a precursor to cervical cancer. The primary cause of CIN is infection with certain human papillomavirus (HPV) types, of which HPV16 is the most...

Papers presented at the 1st European Lung Cancer Conference, jointly organized by the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) in Geneva, Switzerland highlight emerging evidence that common viruses may contribute to the development of lung cancer.Experts agree that smoking is by far the most important factor that contributes to lung cancer development. But other factors can play a role in some cases.In one report at...

LONDON (Reuters) - GlaxoSmithKline's experimental vaccine against a virus that causes cervical cancer could cut the number of cases and deaths from the illness by up to 76 percent, the drug company said on Monday.The vaccine known as Cervarix prevents infection from two strains of the human papillomavirus (HPV) which account for about 70 percent of cases of cervical cancer.In a computer model study sponsored by GlaxoSmithKline and presented at a medical conference in Prague, the researchers...

LONDON -- GlaxoSmithKline's experimental vaccine against a virus that causes cervical cancer could cut the number of cases and deaths from the illness by up to 76 percent, the drug company said on Monday.The vaccine known as Cervarix prevents infection from two strains of the human papillomavirus (HPV) which account for about 70 percent of cases of cervical cancer.In a computer model study sponsored by GlaxoSmithKline and presented at a medical conference in Prague, the researchers predicted...

LONDON -- A vaccine that protects women against a virus that causes cervical cancer is effective for more than four years, researchers said on Thursday.They found that women given GlaxoSmithKline Plc's cervical cancer vaccine Cervarix had high levels of antibodies against two of types of the human papillomavirus (HPV) for up to 4.5 years after receiving their last dose."These findings set the stage for widescale adoption of HPV vaccination for prevention of cervical cancer," said Dr...

LONDON -- A vaccine that protects women against a virus that causes cervical cancer is effective for more than four years, researchers said on Thursday.They found that women given GlaxoSmithKline Plc's cervical cancer vaccine Cervarix had high levels of antibodies against two of types of the human papillomavirus (HPV) for up to 4.5 years after receiving their last dose."These findings set the stage for widescale adoption of HPV vaccination for prevention of cervical cancer," said Dr...

NEW YORK (Reuters Health) - Women with certain types of human papilloma virus (HPV) infection run the risk of developing CIN -- cervical intraepithelial neoplasia, a type of pre-cancer. However, contrary to previous concerns, their risk is not affected if they use hormonal contraceptives, or by their history of pregnancy and childbearing, researchers have found. Previous studies have suggested an increased risk of CIN with long-term oral contraceptive use and having more than one...

By Ransdell Pierson NEW YORK (Reuters) - Girls aged 10 to 14 who received GlaxoSmithKline Plc's vaccine to prevent infection with the virus that causes cervical cancer had immune responses twice as strong as women 15-25 years old given the vaccine, the company said on Saturday, describing results of a late-stage trial. Glaxo said the first published data from a Phase III trial of its Cervarix vaccine suggest it may provide the strongest and most-prolonged protection if given to girls...

By Ransdell PiersonNEW YORK (Reuters) - Girls aged 10 to 14 who received GlaxoSmithKline Plc's vaccine to prevent infection with the virus that causes cervical cancer had immune responses twice as strong as women 15-25 years old given the vaccine, the company said on Saturday, describing results of a late-stage trial.Glaxo said the first published data from a Phase III trial of its Cervarix vaccine suggest it may provide the strongest and most-prolonged protection if given to girls at very...

By Ben HirschlerNEW YORK -- Merck & Co. Inc. is confident its new cervical cancer vaccine Gardasil will win a positive recommendation from a key government group that sets standards for immunizations, a company president said on Tuesday.Gardasil is on schedule to be filed for marketing approval with the U.S. Food and Drug Administration before the end of the year but its commercial success also hinges on the view of the Advisory Committee on Immunization Practices, or ACIP.Margaret...